Circio invites to R&D and corporate update webcast on 28 May 2025
- CTO Dr. Thomas B Hansen will present a summary of recent in vivo results validating circVec performance in novel AAV and DNA formats for gene and cell therapy
- CEO Dr. Erik D Wiklund will provide a corporate and business development update, incl. information related to the upcoming annual general meeting
Oslo, Norway 22 May 2025 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing powerful circular RNA technology for next generation nucleic acid medicine, invites to a live webcast at 10:00am CEST on Wednesday 28 May 2025.
In the webcast, CTO Dr. Thomas B Hansen will present Circio´s latest circVec platform in vivo results. Recent findings include validation of the circVec platform using novel AAV and DNA vector formats, and demonstrate enhanced and distinct tissue expression profiles vs. equivalent conventional mRNA-based vectors. The results highlight potential applications for circVec in tissue targeted gene therapy and in vivo cell therapy; a field that is advancing rapidly and gaining strong momentum in the industry.
CEO Dr. Erik D Wiklund will provide a corporate update including business development activities and background and practical information relating to proposals for shareholder approval at the annual general meeting to be held on 5 June 2025.
Presenters:
CEO Dr. Erik Digman Wiklund
CTO Dr. Thomas Birkballe Hansen
Time: 10:00 CEST on 28 May 2025
Click here to access Teams webcast
Meeting ID: 391 953 079 039 3
Passcode: PB2gk7wt
Questions can be submitted in advance by email to Erik D Wiklund: [email protected] or directly in the live webcast
A recording of the webcast will be made available on the Circio webpage